Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03098030 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT03098030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03098030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Lead sponsor
United Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
June 1, 2017
Completion date
March 26, 2020
Enrollment
483 (actual)
Sites
226

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer